Lilly announces a $15 billion buyback and a seventh straight 15% dividend increase

Eli Lilly's board of directors approved a new $15 billion share repurchase program on December 9, 2024, and announced a 15% increase in the company's quarterly dividend for the seventh consecutive year ^[1]. The dividend for the first quarter of 2025 will be $1.50 per share, payable March 10, 2025, to shareholders of record as of February 14, 2025 ^[1].

The new buyback replaces a prior $5 billion repurchase program that Lilly completed in the fourth quarter of 2024 ^[1]. The company said it expects to carry out the new $15 billion program over the next three years ^[1]. There is no time limit on the authorization, and Lilly said purchases could happen through open market buys, accelerated repurchases, or privately negotiated deals, at management's discretion ^[1]. The program can also be suspended or stopped at any time ^[1].

Lucas Montarce, Lilly's chief financial officer, said the company's capital allocation priorities have not changed even as growth accelerates. He said Lilly will keep funding new drug launches, expanding manufacturing capacity, and investing in research and business development ^[1]. But he added that the company's stronger growth profile means it is also increasing how much cash it returns to shareholders ^[1]. The summary accompanying this news ties the larger payouts to cash flow generated by tirzepatide, the active ingredient in Lilly's diabetes drug Mounjaro and its weight-loss drug Zepbound, though the Lilly press release itself does not break out specific tirzepatide revenue figures ^[1].

Why it matters for patients

This announcement is about Lilly's finances, not about drug prices, insurance coverage, or supply at the pharmacy counter. Buybacks and dividend increases are ways a company returns cash to its shareholders; they don't change the list price of Mounjaro or Zepbound, and the source provided does not say whether they will affect access, manufacturing output, or shortages ^[1].

Still, the scale of the capital return signals that Lilly's board sees the company's cash generation as strong and durable enough to both fund a $15 billion buyback and boost the dividend by 15% for the seventh year running ^[1]. Montarce specifically named manufacturing capacity expansion as a continuing priority alongside the higher shareholder payouts ^[1], which may be relevant to patients who have experienced supply constraints with tirzepatide products, though the press release does not detail specific capacity projects or timelines.

For patients or caregivers who hold Lilly stock, either directly or through retirement funds, the dividend increase and buyback could affect investment returns. For patients simply trying to access or afford these medications, the source does not establish a direct link between this financial news and drug pricing or coverage decisions.

What happens next

Lilly said it expects to execute the $15 billion buyback program over the next three years, with no fixed end date and no obligation to complete it on any schedule ^[1]. The next dividend payment of $1.50 per share is scheduled for March 10, 2025, going to shareholders of record as of February 14, 2025 ^[1]. Beyond those dates, it is not yet known from this source how the buyback pace will unfold or whether Lilly will announce further dividend increases in subsequent years, though the company noted this marks the seventh consecutive year of 15% increases ^[1].